Serine/threonine kinase 11 (STK11) mutations and immunotherapy resistance in patients with non-small cell lung cancer.
posted 3 weeks
Mashup Score: 3
Journal of Clinical Oncology - e15055 Background: There is immune evasion and resistance to checkpoint inhibitors (CPI). Programmed death-ligand 1 (PD-L1) and Tumor mutational burden (TMB) might help us...
Denise Manon Langabeer MBA Ph.D. @MDAndersonNews #ASCO20 #ovariancancer Are symptoms distinguishable in ovarian cancer
posted 1 month
Mashup Score: 2
Oncology Tube - Denise Manon Langabeer, MBA, Ph.D. of MD Anderson gives an overview from ASCO 2020 the abstract entitled Are symptoms distinguishable in ovarian cancer? A...
Oncology Tube - Nikhil C. Munshi, MD of Dana-Farber Cancer Institute discusses ASCO20 Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and...
meetinglibrary.asco.org - 2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2020 American Society of Clinical Oncology (ASCO). All Rights Reserved...
Fight Cancer using your own T-Cells
posted 2 months
Despite recent advancements in immuno-oncology, not all patients with cancer benefit from current treatments, and additional therapeutic options are needed for both hematologic malignancies...
Braunstein Reflects on the Rise of Quadruplet Therapies in Multiple Myeloma
posted 2 weeks
Mashup Score: 1
OncLive - Marc J. Braunstein, MD, PhD, highlights pivotal research on the use of triplet and quadruplet regimens in the up-front and relapsed/refractory multiple myeloma treatment...
Oncology Tube - Robert Coleman, MD, FACOG, FACS, Chief Scientific Officer US Oncology Research discusses ASCO 2020 A phase III randomized controlled trial of secondary surgical cytoreduction...
Andrzej Jakubowiak, MD, Ph.D. @UCCancerCenter #ASCO20 #multiplemyeloma Update of the phase 1/2 EVOLVE study
posted 2 weeks
Mashup Score: 1
Oncology Tube - Andrzej Jakubowiak, MD, Ph.D. of the University of Chicago Comprehensive Cancer Center speaks on the ASCO 2020 abstract Orvacabtagene autoleucel (orva-cel), a B-cell maturation...
ascopost.com - “Declare the past, diagnose the present, foretell the future.” —Hippocrates Outcomes in patients with triple-class–failure relapsed and refractory multiple myeloma who experience disease progression...
Oncology Tube - Paul G. Richardson, MD of Dana-Farber Cancer Institute explains the abstract entitled First-in-human phase I study of the novel CELMoD agent CC-92480 combined with...
OncLive - Michael B. Atkins, MD, discusses the clinical impact of key adjuvant and neoadjuvant data in the melanoma space, as well as the risks and...
Serine/threonine kinase 11 (STK11) mutations & immunotherapy resistance in NSCLC [May 25, 2020] Uba et al. #ASCO20 Abst e15055 https://t.co/3XJMI8cdAX #lcsm #PrecisionMedicine #ImmunoOnc 31/127 STK11 mut, 14 STK11+KRAS mut (SKM group), & 10 SKMP (STK11+KRAS mut+PD-L1 (-))